Company / Return on Equity (ROE)
AYTU BIOPHARMA, INC Return on Equity (ROE) History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-71.5%
FY2025
5-year range
-245.5% / -42.4%
FY2021-FY2025
Trend
-25.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
AYTU BIOPHARMA, INC reports negative total equity of -71.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-71.5% in FY2025 with a 10-year CAGR of -22.0%.
Declined from -43.3% to -71.5% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +174.0pp
- 5-Year Change
- -57.2pp
- 10-Year Change
- -22.0pp
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 25.1% year-over-year.
- Peak return on equity (roe) was recorded in FY2020.
- Lowest return on equity (roe) in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -71.5% | -25.1% |
| FY2024 | -57.2% | -32.0% |
| FY2023 | -43.3% | +82.4% |
| FY2022 | -245.5% | -479.4% |
| FY2021 | -42.4% | -195.5% |
| FY2020 | -14.3% | +81.1% |
| FY2018 | -75.9% | +86.5% |
| FY2017 | -562.7% | -101.4% |
| FY2016 | -279.4% | -464.9% |
| FY2015 | -49.5% | -754.2% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026